Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

EP 100 Trial Finishes Run-In Enrollment

By Drug Discovery Trends Editor | September 7, 2012

Esperance Pharmaceuticals announced the completion of the run-in cohort of its Phase 2, randomized, multi-center trial of EP 100 in combination with paclitaxel for patients with advanced ovarian cancer. EP-100 is a targeted membrane-disrupting peptide (tMDP) designed to seek and destroy cancer cells that over-express luteinizing hormone releasing hormone (LHRH) receptors on their surfaces. LHRH receptors are over-expressed in a wide range of cancers including ovarian cancer. In June, the company presented results from the successful completion of a Phase 1 study of EP 100 in advanced solid tumors at the American Society of Clinical Oncology (ASCO) Annual Meeting.

“We are pleased with the continued momentum behind EP 100 and the progress of enrollment as we begin the randomized treatment phase,” said Dr. Hector Alila, CEO of Esperance. “We are encouraged with early results, and look forward to accelerating enrollment in a very important, underserved patient population and providing an update on the clinical progress over time.”

The randomized, Phase 2 trial of EP 100 in combination with paclitaxel versus paclitaxel alone in patients with histologically confirmed epithelial ovarian carcinomas expressing LHRH-receptors is actively enrolling patients in key clinical sites across the United States. Rationale for the study is based on the positive clinical evidence from escalating doses in 38 patients in the Phase 1 study and on preclinical studies showing synergies between EP 100 and various chemotherapeutic agents.

Date: August 28, 2012
Source: Esperance Pharmaceuticals Inc.

 


Filed Under: Drug Discovery

 

Related Articles Read More >

Roche in Drug Discovery & Development Pharma 50
Roche’s bispecific antibody Lunsumio wins priority review from FDA for non-Hodgkin lymphoma
Tiffany Hurd
CB Therapeutics biz dev lead sees upside for psychedelics in mental health and beyond
Pharmacovigilance
A new era of pharmacovigilance: Worldwide master key for drug safety monitoring
Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50